19 June 2013
Keywords: skye, zileuton, deal, critical, thera, uk, skyepharma
Article | 30 November 2003
The UK's SkyePharma has entered into an agreement with privately-held US firm Critical Therapeutics to develop a controlled-release formulation
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
© 2013 thepharmaletter.com